Register | Forgot password?
Switch to Arabic
Friday, November 27 - 2009

Belgian Pharmaceutical Company Qualiphar-Gifrer signs deal to establish base at DuBiotech

  • United Arab Emirates: Wednesday, April 09 - 2008 at 13:56
  • PRESS RELEASE

Qualiphar-Gifrer, one of the leading pharmaceutical companies in Europe, today signed a partnership agreement with Dubai Biotechnology and Research Park (DuBiotech), a member of TECOM Investments, to set up operations within the life sciences park.

Article continues below
  • Joannes Bruffaerts, Trade Commissioner of Flanders Investment and Trade; Dr. Abdulqader Alkhayat, Executive Director of DuBiotech; Marc Verlinden, Vice President of Qualiphar-Gifrer Pharmaceuticals; Vincent Jadoul, Export Manager of Qualiphar Pharmaceuticals; and Marwan Abdulaziz, Director of Sales at DuBiotech, during a meeting to finalise the partnership agreement between the leading European pharmaceuticals company and DuBiotech, a member of TECOM Investments.
    Joannes Bruffaerts, Trade Commissioner of Flanders Investment and Trade; Dr. Abdulqader Alkhayat, Executive Director of DuBiotech; Marc Verlinden, Vice President of Qualiphar-Gifrer Pharmaceuticals; Vincent Jadoul, Export Manager of Qualiphar Pharmaceuticals; and Marwan Abdulaziz, Director of Sales at DuBiotech, during a meeting to finalise the partnership agreement between the leading European pharmaceuticals company and DuBiotech, a member of TECOM Investments.
Established in 1937 and fully owned by a Belgian family, Qualiphar-Gifrer is a major pharmaceutical player in healthcare products, contract manufacturing and production of plant-herbal extracts. The company is specialised in the development, production and marketing of a wide range of drugs, vitamins, cosmetics and healthcare accessories. Within five years, the company aims to generate an annual turnover of Dhs114m (20m euros) from its DuBiotech operations.

Marc Verlinden, Vice-President and Managing Director for Qualiphar-Gifrer, said: "We are pleased to announce the establishment of our offices in Dubai through our partnership agreement with DuBiotech. This is a major feat that will enable us to meet the increasing demand for our pharmaceutical products in the Middle East.

"Setting up operations in Dubai will allow us to provide the best possible service to our affiliates in the region, as well as to our future partners in the Middle-East, Asia and Africa."


Dr. Abdulqader Al Khayat, Executive Director of DuBiotech, said: "Qualiphar-Gifrer has acknowledged the enormous potential that Dubai offers, particularly in biotechnology, and we are glad DuBiotech is their partner of choice in this first step towards global expansion.

"DuBiotech is committed to creating an advanced technical and community infrastructure for the life sciences industry. In this regard, we are confident Qualiphar-Gifrer will add considerable value to our offerings through conducting research and development on new pharmaceutical products and existing product formulations."

Launched in February 2005, Dubai Biotechnology and Research Park aims to set up a biotechnology industry cluster with appropriate infrastructure, facilities and services for incubators, R&D labs, biotech-related educational institutions, suppliers, biotech and pharmaceutical manufacturing companies.

Offering a complete value chain to help companies set up operations, DuBiotech currently hosts more than 35 licensed firms. The free zone is working closely with the UAE Ministry of Health, the Dubai Health Authority, and other relevant regulatory bodies to further grow the life sciences industry in the country.
Also consider reading:
Log in to request more information from DuBiotech

Notes and media contacts

About DuBiotech
Announced in February 2005, the Dubai Biotechnology and Research Park (DuBiotech) is a science and business park dedicated to the biotechnology industry, set within a 'free zone'. DuBiotech has two arms. The first is the Foundation for Research and Innovation (FRI) that will initially focus on government-funded R&D in medicine and genetics, plant biotechnology encompassing food and agricultural biotech, environmental biotech and equine-related biotechnology. Other areas include drug discovery, stem cell research, infectious diseases and forensic research. The second arm of DuBiotech aims to set up a biotechnology industry cluster with cutting-edge infrastructure, facilities and services for incubators, R&D labs, biotech-related educational institutions, suppliers, biotech-related manufacturing companies and organizations from other sectors in the industry. DuBiotech is advised by an independent steering committee on scientific, business and ethical matters. In cooperation with global research leader, RTI International, DuBiotech is developing comprehensive regulations that address all aspects of biotech activity. Being in a 'free zone' means biotechnology firms in the park have 100 % exemption from any form of taxation for 50 years, 100 % business ownership and 100 % repatriation of capital.

For further information, please call:
Zeba Ahmad
JiWiN
The Exclusive Middle East Affiliate of Burson-Marsteller
Tel: +9714 361 3590 (direct)
+9714 361 3333 (switchboard)
Fax: +9714 388 8001

OR

Cynthia Luna-Harb
JiWiN
The Exclusive Middle East Affiliate of Burson-Marsteller
Tel: +9714 375 5878 (direct)
+9714 361 3333 (switchboard)
Fax: +9714 388 8001

For further information about the pharmaceutical group Qualiphar - Gifrer, please contact:

Vincent Jadoul
Export Manager
Pharmaceutical Group Qualiphar - Gifrer
Laboratoria QUALIPHAR
Dubai Academic City
Building #3, First Floor
Dubai, United Arab Emirates
www.qualiphar.com

Disclaimer:

Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com

Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.

For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions